FDA Finalizes Pre-Submission Facility Correspondence Guidance for Priority ANDA Review Timelines

Generic manufacturers pursuing priority ANDA designations now have a finalized procedural framework from FDA's Center for Drug Evaluation and Research (CDER) governing how pre-submission facility correspondence (PFC) must be structured, and how the Agency will use that information to set binding review goals.

The guidance, issued under docket FDA-2017-D-3101, finalizes a draft circulated on December 5, 2022, and codifies a program enhancement negotiated between FDA and industry under the GDUFA III commitment letter covering fiscal years 2023–2027. For regulatory affairs leads, the practical effect is clear: the PFC is no longer an informal touchpoint but a structured submission with direct consequences for review goal assignment on prioritized ANDAs.

The document specifies which facility information must appear in a PFC and defines the mechanism by which FDA translates that information into a review timeline. Generic manufacturers that submit incomplete or inaccurate facility data risk misalignment between their operational readiness and the Agency's inspection scheduling, a gap that can delay approval independent of the application's scientific merits.

For QA directors and plant heads, the compliance read centers on facility readiness documentation. Prioritized ANDAs, those qualifying under competitive generic therapy (CGT) designations or other priority pathways, attract accelerated FDA review, which compresses the window between submission and potential pre-approval inspection. Ensuring that facility information submitted in the PFC accurately reflects current GMP status, site capabilities, and manufacturing scope is a prerequisite for capturing the review-timeline benefit the guidance is designed to deliver.

The guidance was issued by CDER's Office of Pharmaceutical Quality, signaling that facility-level quality systems data, not just administrative site details, will inform how the Agency sequences its review resources. Comments may be submitted at any time under 21 CFR 10.115(g)(5) via the FDA docket portal or in writing to Dockets Management, FDA, 5630 Fishers Lane, Rm 1061, Rockville, MD 20852, referencing docket FDA-2017-D-3101.

With GDUFA III performance goals now governing Agency review commitments through FY2027, the accuracy and completeness of each PFC submission becomes a measurable variable in a generic manufacturer's speed-to-market calculus.

Source: FDA Center for Drug Evaluation and Research via FDA.gov Guidance Documents feed, July 10, 2026.